Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
12.02
+0.12 (1.01%)
Nov 4, 2024, 4:00 PM EST - Market closed
Replimune Group Employees
Replimune Group had 331 employees as of March 31, 2024. The number of employees increased by 47 or 16.55% compared to the previous year.
Employees
331
Change (1Y)
47
Growth (1Y)
16.55%
Revenue / Employee
n/a
Profits / Employee
-$664,686
Market Cap
821.22M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Healthcare Services Group | 33,400 |
Avanos Medical | 3,771 |
InnovAge Holding | 2,350 |
Embecta | 2,200 |
Adaptive Biotechnologies | 709 |
AbCellera Biologics | 586 |
Sana Biotechnology | 328 |
EyePoint Pharmaceuticals | 121 |
REPL News
- 5 days ago - Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire
- 26 days ago - Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 2 months ago - Replimune: Strong Data In A Highly Differentiated Space - Seeking Alpha
- 3 months ago - Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma - GlobeNewsWire
- 3 months ago - Replimune to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma - GlobeNewsWire